Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer

Kenji Nemoto, Haruo Matsushita, Yoshihiro Ogawa, Ken Takeda, Chiaki Takahashi, Keith R. Britton, Yoshihiro Takai, Shukichi Miyazaki, Tsuyoshi Miyata, Shogo Yamada

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)

Abstract

From January 1999 to November 2000, a total of 24 esophageal cancer patients (17 untreated and 7 recurrent cases) were treated with radiation therapy (60-70 Gy) combined with cis-diammine-glycolatoplatinum (Nedaplatin) (80-120 mg/body) and 5-fluorouracil (5-FU) (500-1,000 mg/body/24 h, continuous infusion for 5 days). Grade III leukocytopenia was observed in 6 (25%) of the patients. Grade III and IV thrombocytopenia was observed in one patient each. The 1-year and 2-year survival rates for definitively irradiated patients were 59% and 39%, respectively, and for patients with postoperative recurrence 69% and 69%, respectively. High-dose radiation combined with Nedaplatin and 5-FU is a safe and effective method for treating esophageal cancer.

Original languageEnglish
Pages (from-to)46-49
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume26
Issue number1
DOIs
Publication statusPublished - 2003 Feb 1

Keywords

  • 5-FU
  • Chemotherapy
  • Esophageal cancer
  • Nedaplatin
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer'. Together they form a unique fingerprint.

Cite this